Corneal collagen cross-linking now at Perimeter
There is growing evidence that collagen crosslinking treatments can stabilize the cornea and help visual acuity in eyes with keratoconus, and possibly in those who experiencing ectasia (bulging of a thinned cornea), a complication that can follow LASIK surgery.
At Emory Eye Center’s Perimeter Clinic, a clinical trial (2008–2010) revealed that at six months there was significant difference in the eyes treated with collagen cross-linking and those that were not treated. The treated eyes remained stable while the control eyes worsened.
Today, Emory Eye Center offers the latest crosslinking system, KXL, a new treatment that reduces cross-linking treatment time from 30 minutes to less than five minutes. During cross-linking treatment, riboflavin drops are administered to the eye and UVA light is aimed at the cornea. The light causes the riboflavin to fluoresce, which leads to the formation of bonds between collagen molecules, resulting in collagen crosslinking. The bonding then helps create stronger and more stable cornea tissue, potentially preventing acceleration of the keratoconus or ectasia. The treatment is still offered in the context of a multi-center FDA clinical trial.
“We are extremely excited to again be able to offer collagen cross-linking treatment to our patients with keratoconus, as this treatment is the only strategy available to be able to halt, and in many cases partially reverse, the progression of this corneal disease,” says Brad Randleman, director, cornea, external disease and refractive surgery. “In the United States, we have been far behind the rest of the world in terms of what we have been able to offer these patients. Now, with the KXL system, we again are able to provide the latest and best treatment for our patients.”